Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study

Article information

Intest Res. 2024;.ir.2024.00044

Publication date (electronic) : 2024 May 22

doi : https://doi.org/10.5217/ir.2024.00044

Kijae Jo^1,*, Kwang Woo Kim^2,*, Hyun Jung Lee¹, Jong Pil Im¹, Joo Sung Kim¹, Seong-Joon Koh^,1

¹Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

²Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

Correspondence to Seong-Joon Koh, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea. Tel: +82-2-740-8112, Fax: +82-2-743-6701, E-mail: jel1206@snu.ac.kr

*These authors contributed equally to this study as first authors.

Received 2024 March 20; Revised 2024 April 10; Accepted 2024 April 15.

Abstract

INTRODUCTION

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that is limited to the colon and is characterized by continuous mucosal inflammation and subsequent symptoms, such as diarrhea and hematochezia [1,2]. The prevalence has been increasing globally over the past 2 decades, particularly in East Asian countries, including Korea; due to Westernization and urbanization in this region [3-5]. The exact pathophysiological mechanisms have not been established; however, they are believed to be caused by a combination of various factors, including genetic disposition of the host, mucosal immunity, and an imbalance of the intestinal microbiome [1,6-8].

Several molecules involved in the inflammatory cascade, such as tumor necrosis factor-α, interleukin (IL)-12, and their receptors have been identified. Moreover, a number of biologic agents and small-molecule drugs have been developed to target them, revealing excellent therapeutic responses; and they are used as first-line treatment [1,9-12]. New drugs targeting other mechanisms are additionally in research and development [13,14].

In the interim, the Selecting Therapeutic Targets in Inflammatory Bowel Disease-II Initiative has expanded the goal of treatment for IBD from conventional, symptomatic clinical remission to endoscopic remission. This has resulted in the use of objective markers, absence of disability, and restoration of quality of life with prognostic considerations [15].

More recently, targeted treatment has been expanded to include histological mucosal healing [16,17]. Findings of meta-analysis by Yoon et al. [18] have revealed that patients who achieve histological remission have a lower risk of relapse and better prognosis than that of those who do not. Furthermore, Chateau et al. [19] have suggested expanding the treatment goal of UC to histological remission. However, each patient possesses a different course of disease and responds differently to drugs, with some patients not responding at all or their response regressing quickly, making it challenging for clinicians to select the appropriate biologic agents [7,20]. In addition, due to the high cost of biologic agents, the economic burden on patients and overall healthcare costs have tended to increase, intensifying the demand for predicting the response to biologic agents, in order to be administered to the appropriate patients [21,22]. Several studies have reported predictors of response and remission regarding biologic agents; however, these studies were conducted primarily in Western populations. Thus, these predictors are difficult to apply to the Korean clinical setting, due to racial differences [7,23,24].

Therefore, in this study, we identified the predictors of histological remission after first-line biologic agent and small-molecule drug treatment in patients with biologic agent-naïve UC. We hypothesized that biological agents can appropriately be administered to patients, to improve prognosis and reduce the associated healthcare costs.

METHODS

2. Study Design and Definition of Variables

We conducted a single-center, retrospective cohort study and collected data on patients with at least 1 diagnosis related to UC (K51 code in the Korean Standard Classification of Diseases and Causes of Death) and recorded minimal 1 dose of infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, or tofacitinib, between January 1, 2015 and December 31, 2022 (Fig. 1). Of the 411 patients, 92 patients were included in the study.

Fig. 1.

Flowchart of subject selection. UC, ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; AS, ankylosing spondylitis.

The exclusion criteria were as follows: (1) patients who were prescribed biological agents and small-molecule drugs for other immune-related diseases; however, the diagnosis was incorrectly recorded; (2) patients transferred from other hospitals; thus, no data were available at our center; (3) patients without baseline biopsies; (4) patients who were administered an inappropriate regimen; (5) patients who were administered drugs, without proper endoscopic evaluation; and (6) pediatric patients.

Subsequently, the clinical information, medical history, laboratory test results at the time of diagnosis, and endoscopic and histological findings pre- and post-treatment with biologic agents and small-molecule drugs were retrospectively reviewed.

Medical history included age, sex, body mass index (BMI), date of diagnosis, smoking history, underlying medical conditions, disease extent at diagnosis, and endoscopic severity. Laboratory tests included the complete blood count, albumin level, erythrocyte sedimentation rate, C-reactive protein, fecal calprotectin, antineutrophil cytoplasmic antibody, and anti-Saccharomyces cerevisiae antibody. The full Mayo score and endoscopic and histological findings at the time of the initiation of the biological agent were reviewed. Additionally, the 1-year post-treatment follow-up endoscopic and histological findings were assessed. Colonofiberscopy (CFS) was performed by an experienced endoscopist and evaluated using the Mayo endoscopic score (MES). Tissue samples were obtained from active lesions, and random biopsies were performed for patients in remission.

The Elderly onset of UC was defined as being diagnosed at the age of ≥ 65 years, as per a previous definition [25]. Smoking status was defined as, “ex-smoker,” “current smoker,” or “never smoked,” according to the patient’s in-clinic response. The BMI was measured in kg/m². The Asia-Pacific BMI classification was used to categorize underweight, normal, overweight, and obese as < 18.5, 18.5–22.9, 23.0–24.9, and > 25.0 kg/m² respectively [26].

Endoscopic remission was defined as 0–1 on the MES. An improvement in the MES was defined as a decrease of ≥ 1, from the baseline to the follow-up CFS.

Histological remission was defined as the absence of active cryptitis, crypt abscess, and inflammatory cell infiltration on microscopic examination by an experienced histopathologist [17,27]. A comparative analysis of the clinical characteristics between patients with and without histological remission on follow-up endoscopic biopsies was conducted.

RESULTS

1. Baseline Demographics and Patient Characteristics

Of the 92 patients included in the study, 25 (27.2%) achieved histological remission, after first-line biological agent treatment. The baseline characteristics of the 2 cohorts are presented in Table 1. The median age at diagnosis and sex ratio did not differ between the 2 cohorts. The mean BMI did not differ statistically significantly between the 2 cohorts; however, the proportion of patients who were overweight was statistically significantly higher in the remission cohort than that in the non-remission cohort (48.0% and 16.4%, respectively, P= 0.026). Statistically significant differences in the comorbidities were not observed between the 2 cohorts.

Table 1.

Baseline Clinical Characteristics of the Histological Remission and Non-Remission Cohorts Are Depicted

At the time of diagnosis, statistically significant differences were not observed in the disease extent and MES between the 2 cohorts, and most patients had a MES of 2–3. Regarding the laboratory test results, the hemoglobin and albumin level were statistically significantly higher in the remission cohort than that in the non-remission cohort (P= 0.022 and P= 0.002, respectively). Laboratory results revealed no other statistically significant differences between the 2 cohorts. Before first-line treatment with biologic agents, the Mayo score and MES did not differ statistically significantly between the 2 cohorts; and all patients had moderate-to-severe disease and a MES of 2–3. In addition, histological activity on pretreatment biopsy was observed in 92% and 97% of the patients in the histological remission and non-remission cohorts, respectively.

2. Trends in First-Line Biologic Agents and Small-Molecule Drugs

Trends regarding first-line treatment with biologic agents are shown in Table 2. No statistically significant differences in the time taken from diagnosis to first use of the biological agent were observed between the remission and non-remission cohorts (665 days and 1,118 days, respectively, P= 0.109). Infliximab, vedolizumab, adalimumab, ustekinumab, tofacitinib, and golimumab were used as first-line biologic agents and small-molecule drugs in the order listed, with no statistically significant differences between the 2 cohorts.

Table 2.

Trends Regarding the First-Line Biologic Agents and Small-Molecule Drugs in the Remission and Non-Remission Cohorts Are Depicted

3. Results of Follow-up Studies and Endoscopic Improvement

The results of the first-line treatment with biologic agents are summarized in Table 3. At follow-up, complete remission was revealed in 16 (64.0%) and 2 (93.0%) patients in the histological remission and non-remission cohorts, respectively. Moreover, 8 (32.0%) and 23 (34.3%) patients showed endoscopic improvement, in the histological remission and non-remission cohorts, respectively (P< 0.001). Compared to pretreatment CFS, all patients in the histological remission cohort showed an improvement in the MES; nonetheless, in the non-remission cohort, an improvement was only observed in 49.3% of the patients (P< 0.001).

Table 3.

Results of the Follow-up Studies and Endoscopic Improvement in the Remission and Non-Remission Cohorts Are Depicted

4. Univariate and Multivariate Analysis for Predictors of Histological Remission

Results of the binomial logistic regression analysis, identifying statistically significant predictors of histological remission are presented in Table 4. In the logistic regression analysis to identify predictors of histological remission, the Asian-Pacific BMI classification, albumin, azathioprine usage, and class of firstline biologic agents were found to be statistically significant predictors in the univariate logistic regression analysis. In the multivariate logistic regression analysis, the overweight category of the BMI was found to be a statistically significantly stronger predictor of histological remission than normal weight (OR, 3.883; 95% CI, 1.141–13.212; P= 0.030).

Table 4.

Univariate and Multivariate Logistic Regression Analysis for Predictors of Histological Remission

DISCUSSION

This study identified predictors of endoscopic and histological remission after first-line therapy with biologic agents and small-molecule drugs, in patients with biologic agent-naïve UC, in real-world clinical practice.

Previous studies have shown endoscopic remission rates ranging from 29% to 60%, depending on the agent, and this study revealed an endoscopic remission rate of 57.2% [13,28,29]. Histological remission rates for current UC treatments range from 15.0% to 44.9%, according to drug class and patient population [30]. The histological remission rate was 23.8% in this study. Although the endoscopic and histological examinations were not performed according to uniform protocols due to retrospective nature; nevertheless, they were evaluated by trained endoscopists and histopathologists. Moreover, the results are consistent with those of previous studies.

In our study, on follow-up endoscopic biopsies, we found that patients who were overweight were statistically significantly more likely to achieve histological remission than patients of a normal weight. This can be explained by obesity being a poor prognostic factor in the course of immune-related diseases, including UC [31,32]. The distribution of the drug in patients who are obese is different from that in patients who are of a normal weight. This is due to the increase in body fat composition, which results in different activation rates in the body [33]. Additionally, pro-inflammatory adipokines secreted by the immune cells of adipose tissue and an imbalance in the gut microbiota have been found to influence the pathophysiology of UC, by exacerbating the overall inflammatory cascades [34-36].

In addition to the increased proportion of adipose tissue in obesity, sarcopenia, a decrease in skeletal muscle mass, is theorized to play a role in the inflammatory response [37-39]. A systematic review by Fatani et al. [39] has confirmed that 17% of patients with IBD have sarcopenia, which is associated with the risk of surgical and medical treatment failure. Findings of a prospective cohort study by Liu et al. [40] have revealed that sarcopenia in patients with IBD is associated with poor clinical outcomes, such as increased rates of surgery (OR, 6.651; P< 0.001), re-hospitalization (OR, 6.344; P< 0.001), and mortality (P= 0.003) in IBD. Cushing et al. [41] have confirmed that sarcopenia as determined by abdominal computed tomography is a poor prognostic factor (OR, 3.98; P= 0.033) for acute, severe UC, requiring further treatment. This is due to the secretion of myokines by skeletal muscles, such as IL-6 and IL-15, which exert direct anti-inflammatory effects and inhibit the release of pro-inflammatory adipokines from visceral fat [42]. In a murine model of colitis with increased physical activity, symptoms of colitis symptoms were significantly reduced by diarrheal episodes. Immunological changes, such as decreased regulatory T-cells and tumor necrosis factor-α secretion; as well as enhanced secretion of a well-known anti-inflammatory cytokine, IL-10 have been identified [43-45].

Past research has shown that the BMI does not accurately reflect actual skeletal muscle and fat mass. Possessing a large amount of skeletal muscle mass can distort the BMI into that of the overweight category, which is a numerical limitation of BMI [46]. In the present study, accurate body composition was not measured by a body composition analyzer, such as InBody® (InBody Co.) or abdominal computed tomography; however, the inference was that the patients who were overweight had relatively more skeletal muscle mass than did the other patients. Patients with UC may have a poor oral intake, due to chronic abdominal symptoms. Furthermore, they are relatively susceptible to sarcopenia, due to repeated steroid use and reduced physical activity. Thus, maintenance of the skeletal muscle mass may predict a better disease course and good response to biologic agents. Lifestyle modifications, such as nutritional education, weight management, and encouragement of physical activity in patients with sarcopenia or sarcopenic obesity may improve the treatment response to biological agents [42,45,47,48]. However, previous studies have not confirmed a direct correlation between sarcopenia and biologic agent treatment failure, and further studies with precise designs are required [49].

Our study had several limitations. First, due to the retrospective nature of the study, the examination protocols were not standardized; and the timing of blood tests, endoscopies, and histological examinations were inconsistent. Selection bias may have been induced by excluding patients who did not have the biopsies required for this study. Second, many patients did not undergo laboratory tests, such as fecal calprotectin, at the discretion of the attending clinician; therefore, data was missing. Third, due to the small population size, limited to a single-center, we included multiple biologic agents and small-molecule drugs with different pharmacological actions. This made it difficult to identify the predictors of remission for each agent. Still, the choice of biologic agents and small-molecule drugs as first-line treatment for patients with biologic agent-naïve UC should be based on the insurance policy of the region, unique characteristics of the drug, route of administration, patient preference, cost, and consideration of existing head-to-head trials.

Despite these limitations, this real-world study identified predictors of histological remission after first-line treatment with biologic agents and small-molecule drugs in patients with biologic agent-naïve UC. This is the first study conducted in Korea that has identified predictors of histological remission in patients with biologic agent-naïve. The predictors identified in this study can be used to improve patient outcomes and reduce healthcare costs, by appropriately administering biologic agents to patients expected to achieve histological remission.

In conclusion, this retrospective cohort study confirmed that the overweight category of BMI is a statistically significant predictor of histological remission. Further prospective and translational studies with a molecular basis are required to confirm these findings, and to improve the prognosis.

Article information Continued